CAR-NK cell therapy for cardiac amyloidosis
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new cell therapy, CAR-NK, for people with amyloidosis that has affected their heart and hasn't responded well to initial treatments. The goal is to see if the therapy can help control the disease and improve heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with amyloidosis that involves your heart, shown by thickening of the heart wall or high NT-ProBNP levels.
- You have tried at least one standard treatment (like bortezomib or a CD38 antibody) and your disease didn't improve enough.
- You have measurable signs of disease, such as abnormal protein in your blood or urine.
- You are in generally stable health, with adequate organ function (like kidney, liver, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a three-drug combination (selinexor, daratumumab, and dexamethasone) for people with a specific type of amyloidosis that affects the heart. The goal is to see if this treatment can help reduce the abnormal proteins causing the disease and improve symptoms.
This trial tests a type of immunotherapy called CAR-T cells for people newly diagnosed with severe AL amyloidosis, a disease where abnormal proteins damage organs, especially the heart. It aims to see if this treatment can help control the disease.
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
This trial tests a type of immunotherapy called CAR T cells that target a protein called BCMA on abnormal cells. It is for people whose light chain amyloidosis has come back or not responded to previous treatments.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
Hear when a new Light Chain Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.